Prop 38 Would Fund Immunology With $8.4 Billion
California voters decide on November 3, 2026 whether state bonds should finance immunotherapy research that repays itself from research revenue.
Updated on Nov. 3, 2026 in Biotech

Live Poll
Should California borrow $8.4 billion in bonds to fund immunology research?
California voters are weighing Proposition 38 on the November 3, 2026 ballot, which would authorize the state to sell $8.4 billion in bonds to finance immunology research and therapies at state institutes and universities. The measure is a proposal, not an enacted program; no funds exist until voters approve it.
Why it matters
The measure ties a large public research budget to a repayment model in which 10% of revenue from funded research goes back to the state, a structure that tests whether public bond money can recover its cost through commercialized science. It arrives as federal medical research funding has been cut, putting state-level financing of immunotherapy research in sharper focus.
The measure splits $8.4 billion in authorized bonds evenly between one University of California-affiliated nonprofit research institute and research grants, with 10% of revenue from funded research directed to the state. CalMatters' reporting found the eligibility criteria would leave only one qualified institution, the California Institute for Immunology and Immunotherapy, though how that finding will hold up under the campaign debate remains unsettled.
The players
Gary Michelson
Retired surgeon and billionaire inventor of medical devices who has donated over $40 million to the Yes on Prop. 38 campaign and founded the California Institute for Immunology and Immunotherapy.
Robert Kaplan
Senior scholar at the Stanford University School of Medicine and co-chair of the No on Prop 38 campaign.
Alzheimer's Association
Major national Alzheimer's advocacy and research organization that supports Proposition 38.
Michael J. Fox Foundation for Parkinson's Research
Parkinson's disease research organization that supports Proposition 38.
The details
Proposition 38 would let the state sell bonds and use the proceeds to finance immunology research and immunotherapy therapies, the approach of training the immune system to target disease such as cancer. Half the money would go to a single nonprofit medical research institute affiliated with the University of California, and half to research grants. The measure is designed to pay for itself: revenue from funded research must first flow into the state General Fund until it repays the bond principal plus interest, after which surplus would fund further immunology work.
Timeline
November 3, 2026: California voters decide Proposition 38 on the statewide ballot.
The Tech Race
Proposition 38 positions California as a state financing its own immunotherapy research as federal grants to universities and medical centers have been cut. Whether bond-funded research can return its cost through a revenue share is an open question that other state science programs will watch.
If approved, the bonds would finance immunology research and therapies at state institutes and universities, but no therapies or programs exist yet and timelines depend on the bond sale and institute setup. Voters are the only near-term decision point, on November 3, 2026.
The takeaway
Watch the November 3, 2026 vote and whether the eligibility criteria, which CalMatters found would leave only one qualified institution, become a central campaign issue. The repayment timeline, which could stretch for decades under the 10% revenue requirement, will determine whether the measure is viewed as self-financing.
Further reading
For the broader research-funding context behind this measure, see the Biotech coverage on California's approach to public science financing.
Live Poll
Should California borrow $8.4 billion in bonds to fund immunology research?





